Dr Juan Badimon (The Mount Sinai School of Medicine, New York, NY, US) discusses the results of the EMPA-TROPISM trial, which investigated the safety and efficacy of the SGLT2 inhibitor empagliflozin versus placebo on top of guideline-directed medical therapy in heart failure patients with reduced ejection fraction (HFrEF) without diabetes. Its hypothesis was largely designed to assess if the cardiac benefits of empagliflozin as previously shown in EMPA-OUTCOME, could be extended to non-diabetic HF patients.
1. What was the rationale for this trial?
2. What was the design, patient populations and endpoints?
3. What were the key results and what conclusions can be made?
4. What are the clinical implications of this data?
5. What are the 'take-home' messages for clinicians?
Recorded remotely from New York, 2020.
Interviewer: Victoria Perroud
Recording Editor: Josh Birch, Natascha Wienand